Refractory Disease — Treatment-Resistant Cancer

Refractory disease refers to a state of therapeutic non-responsiveness where malignant tissue fails to undergo cytoreduction or stabilization despite the administration of standard antineoplastic regimens. It represents intrinsic or acquired drug resistance, demonstrating ongoing tumour proliferation or radiographic progression during active therapy or within a short, predefined interval following treatment cessation.

Mechanistically, refractory disease emerges through diverse biological pathways. These include somatic mutations within targeted drug-binding pockets, overexpression of adenosine triphosphate (ATP)-binding cassette efflux pumps, activation of alternative oncogenic bypass signaling cascades, loss of pro-apoptotic mechanisms, and microenvironmental factors such as immunosuppression or poor drug penetration. In haematology and medical oncology, establishing that a disease is refractory necessitates switching to alternative therapeutic classes.

Recognizing refractory disease is essential for preventing continued exposure to ineffective treatments and their associated toxicities. When a cancer is confirmed to be refractory, patients and doctors must rapidly pivot to consider second-line therapies, targeted biological agents, immunotherapies, or clinical trials evaluating investigational drugs. It also prompts meaningful conversations about patient priorities, symptom management, and quality of life.

Refractory status is determined through objective restaging evaluations, including CT, MRI, or PET-CT scans demonstrating tumour growth (such as RECIST criteria progression). Rising serum tumour markers (e.g., PSA, CA-125) also provide evidence. Repeat tissue biopsies or liquid biopsies (circulating tumour DNA) are often performed to identify specific resistance mutations.

Refractory states occur across both solid tumours and haematological conditions. Common examples include refractory diffuse large B-cell lymphoma (DLBCL), refractory multiple myeloma, platinum-refractory ovarian and bladder cancers, castration-refractory prostate cancer (CRPC), and refractory acute myeloid leukaemia (AML).

Declaring a cancer refractory prompts an immediate cessation of the ineffective regimen. Next steps depend on molecular profiling and prior exposures. Options may include novel targeted therapies, antibody-drug conjugates, immunotherapies, chimeric antigen receptor (CAR) T-cell therapy in lymphomas, or experimental protocols in early-phase clinical trials, alongside palliative care.